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Introduction 
Onhotopic live-r transplantal ion (OlT) has bC"Come- an 
cslablishe-d and acee-pled me\hod in end -slagc liver 
disc-asC"S. U [n spile- of Idint<! surginl t«hniques, 
blccding re-mains a eli liea[ probkm , influencing sholt · 
and 10ng' lerm outrome-.l 
Obviously, the re-p laccment of an insufficie-mly 
fuOCliomJ live-r by a [ive-r graft h:u a eOll$ickrllbk impa<1 
on the coagulalion and fibri nolytic systems. Pte-.nisting 
distutbancC"S of hacmO$l:uis due- 10 impaire-d symhesis 
of douin, faClOI"$ aod inhibitors, as wdl :u reduced 
cle-araoce- of PIOIe-a.sc:S and protca5C.inhibitor eomplexes 
by thc re-cipie-nt's live-r , may bccome funher aggnvll.ICd 
inna-opcrlltlvdy . 
During the- late anhe-pal ic and the- tarly !e-pc::rfusion 
phasC"S of OLT, signs of hyperfibrinolysis may bc of 
causat.ivc imponancc for intra , and posl·ope-rativC" 
bke-din, .1-6 In addi tion , prolh!ombin bCCOffiC"S 
actlvalC"d during OlT, pcaJc.ing in the !eperfusion 
pha.sc: .4.6 The- rok of ,he- livC"r graft and its perfUsale- in 
Ihe- hacmosutic babncC" aftC"! re-pcrfusion ha ve- bccn 
ciiscuntd-l 6 bUI nOI pre-viously inve-sligale-d . 
Aprolinin, a patemcl1llly administcre-d prole-ina.sc: 
inhibilOr from bovine- lung,7.0 inhibin kallikrein, 
an impollant activa tOl of comael aeliVition, triggering 
the- intlinsie coaguJation (a5Cade as ... ell as the- intrinsic 
fibrinolYIK sys ttm . '0.11 In addition . aprotinin inh ibiu 
pl:umin , uypsin and, 10 SQme C"Xtent, human uro· 
kinasc- .3 Thc 10xicilY of apIOlinin i$ exn emdy 10"" and 
the- tole-rability of vcry high dosts is goad/· ll 
In the- pre-S(nt sludy, ... t investigalcd rc levam 
paramC"tC"r$ of the coagulat ion and fibr inol Yl ic sysrtffiS 
in samplts ,ahn in the- course- of tcn conSC-CUli ve- OL Ts 
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when aprolinin was adminislered inna-opc:rat iYc:ly_ In 
addition. we inyc:stigalc:d for ,he first time (he liyer graft 
pc:rfusate 10 c:stablish iu connibution [0 roagulation 
(hanges after repc:rfusion. 
M:aleri:als :and methods 
A conS«utive st ries of 10 palienu ",i th terminal liver 
disc:a.se (Table I) underwem (heir fiest OlT at the 
UniyersilY Hospital Rudolf Virchow, Charlottenburg . 
bcrween 19 August 1989 and 23 November 1989. O lT 
was pc:rformed by standard tIXhniques using a veno-
venous bypass.n.l• 
The hQ5{ liver was mobilizc:d. during {he ple-anheparic 
phase:. The anhepatic phase: begins wilh ocdusion of the 
blood flow tO the host liver and ends wirh the insc:rtion 
of the liver graft in the patien($ ei[culat ion. Tbe 
repc:riusion phase: las ts untilthe end of sutgery. 
Packed red blood ceUs (RBC) and fresh-frozen plasma 
(FFP) were ustd 10 compc:n$2.le for iml1l,opc:lative blood 
loss. Bc:fore me anhepatic phase: . at the end of Ihe 
anhepalic phase: and 1 h after repc:rfusion. 0 . 5 .. 106 
Kallikecin InaCliVlitor Uniu (KlU) aprotinin (Tr:uylol . 
Bayer. Lcverkusc:n. Germany) were giyen inlfavenously. 
For cold storage of (he grafl liver Iklzer UW-CSS 
sohllion (Du Pom, Paris. France) was uscd. 
Blood sampies weee taken from the atterial line, afler 
ioduetion of al12c:smcsia (1). 5 min bc:fore (2) and 10 min 
after (3) the kginning of the anhepalic stage. 5 min 
before thc:repc:rfusion phase: (4). and 5 min (~) . 15 min 
(6), 60 min (7) and 12 h (8) after repc:rfusion. In 
addition. a sampie of thc: pc:rfusate rc:lc:asc:d from thc: liver 
gl1lft vein by flushing wim anerial blood, was taken 
kfole opening the hepato.caval anastomosis (P). Blood 
samplc:s were anticoagulatc:d with a 1/10 voJumc: of 
[risodium citl1lte :ltld. in addition . aliquotS wele atidific:d 
with acet«: :acid for the determination of tissue.typc: 
plasminogen activator (rPA) and urokina.sc.typc: plasmin-
Tabk I. OiaC"""i, and <ba ...... ,;,,,CI of 10 pni.n .. und'faoin, 
on ..... opoc ~...,. uansplltu .. ions 
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ogen aetivator (uPA) acrivities. Another blood sample 
was am;coagulated with a miKture of rri.sodium ciuate. 
{heophylJine. adenosine and dipyridamole for the 
detetminarion of plasminogen Ktivator inhibitor Kriviry 
(PAI). The spc:cimens were gendy mixed and cemrifugc:d 
at 3000 rpm fot 20 min and (he supc:rnatam frozen al 
- 70·C. Whole blood amicoagulalc:d wirh trUodium 
eluate was uscd for thrombodastogC2phy (TEG). 
The following parameters were mea.sured u$ing 
eommercially available kiu: D-dimer. fibrin monomer, 
free protein Santigen. protein C aClivity (Boc:hringer 
Mannheim . Mannheim. Germany). antithrombin 111 
aerivity . plasminogen actlvity. alpha.2.amiplasmin 
aetivlty. Cl-inhibitor ~tiv it y (Bc:hring Werke AG. 
Matburg. Germany) and fibrinogen according tO Clauss 
(Hoffmann-la Roche. Base:l, Swjl~erland) . 
tPA aod PAI :activitic:s ~re determined by using a 
dllOmOgenic subsuate melhod and tPA amigen was 
mea.surc:d in a solid.phase enzyme immunoway (Kabi. 
Stockholm . Swcden). 
An immunosorbent activity auay for the combined 
determination of single-chain uroklnase:-typc: plumin. 
ogen aCli""tor (scuPA) and I",o-chain urokinase:-typc: 
plasminogen aeti""tor (tcuPA) activitic:s was u~d 
(Biopool . Umea. Sweden). UPA antigen was c:stimated 
by an enzyme immunoassay (Biopool). Plasmin.alphil-2· 
antiplasmin rompluc:s (PAP) wcre detcrmined by an 
enzyme immunoassay (T«hnoclone. Vienna. Auslria). 
Thrombin - antilhrombin III (TAT) complc:xc:s were 
determined by an enzyme immunoassay (Bc:hring Werke 
AG. Matburg. Gc:rmany). Aprorinin wu eslimated by 
enzyme immunoway according to Mueller-Esterl. L~ 
TEG of r«alcified whole blood was pc:normed using 
a thrombodastograph (Hellixe. Freiburg. Germany). 
Whole·bJood dOI lysis times (WBLTs) (rhe time bc:tw«n 
t~ maximal amplitude and complele lysis in Ihe TEG) 
bc: low 90 min. or betw~n 90 and 120 min. wete Iden 
tO indicare sc:vere or mild hypc:rfibrinolysis. lespc:ctivc:ly. 
Slalisticm ,mal,s" 
1bc: significance of differentc:s ",imin glOups were test~ 
using the Wilcollon rank-sum test. Valuc:s for P < 0.05 
were considered 10 be significanr . 
Results 
The blood usc:d duting me 0pc:l1ltion and one 10 thrce 
days after OLT is shown in Table 2 . 
In TEG, signs of in(reasing fibrinolytic aClivation 
bc:c-amc: appatent dur;ng the course: of each CLT Two 
patienu had sii;fU of .mild and three pauc:nu $i~fU of 
sc:vere hy~rfibllnolys,s (see above) in at Ic:a.sl one blood 
sampie. Signs of hypcrfibrinolysis occurred filsl at me 
end of rhe anhepatic phase: in theee and in the early 




RBC (uni .. ) 
" 
~ - 26 
F1'P (uni,.) 1 - 39 




FfP (uni .. ) • o· 1} 




FfP (uniu) • 0 - 16 
r~perfusion ph:i.S(: in twO of t h~ livc pari~ms wirh dearly 
aceelerated librinolysis. 
Levels of IPA aclivi ly and anligen inctc:i.S(:d during Ih~ 
pr~·anheparic and anh~patic phases wilh maxima al 
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the end of Ih~ anh~palic phas~. Thc d~dine observed 
imm~diately afler rcperfusion became significam aft~r 
60 min for Ihe IPA activilY [P(415) .. 0.006] and afl~r 
15 min forthetPA antigen [P(415) ., 0.OO3](Figurc I). 
Plasma levels of PAI act ivi ty did nOI change signifi. 
cantly dUling Ihe pr~·anh~pali{ and anh~palic phases. 
Sixly minul~s and 12 hafter reperfusion lh(!~ wer~ 
significant elevalions in comparison wilh Ihe pre· 
operative I~vels (Figure t). 
UPA aClivily show~d a significant incrc:i.S(: in the 
anhepatic phase with a maximum al Ihe ~nd of th~ 
anhepatic ph:i.S(: (Figulc 2). uPA antigen increased 
significantly afl~l rcperfusion wh~ reas Ihe C,·inhibilor 
dectc:i.S(:d significantly at the same time [P (4/5) -
0.004] (Figur~ 2). 
PAP levcls(n ,.. 3) inctc:i.S(:d in parallel with tPA and 
uPA activitie5 during Ih~ anh~pal ic phase and dccr~:i.S(:d 
in Ihe reperfusion ph:i.S(: (Figur~ 3). 
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D·dime:rs "'en: significamly highe:r ar the end of the: 
anhcpuK phuc: than in the: pre:.anhe:palic phase (Fillure: 
' ). 
TAT compkxes and fi brin monome:rs incle:a.scd 
significamly imme:dia rc:l y afu:r re:perfusion (f igurc 4), 
whe:reu AT HI aelivity and free prolcin S am igen 
demonslfaled a significant fall after .e:perfusion (figure: 
'). 
Aerording to thc imermillent bolus :ldminiSiration of 
aprolinin . peak levels "'ere scc:n befo.t" rhe anheparic 
stage, at the e:nd of thc anhepa, ic phase- and 60 min aftef 
reperfusion (figUfC 6). 
TAT complc:xes and uPA aclivity in the perfusalC We:fe: 
significamly de:vate:d as compare:d wilh plasma sampIes 
of ,he: s)'$te: mic cilCulation laken immediarely befo.e 
.eperfusion, whe:.e:u tPA amige:n, fibri nogen and . mosl 
pronounee:d . thc activities of the prolcast inhibito.s 
C,· inhibiIOI. AT 111 and pro'ein C ",e:re significam ly 
, 
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de:(fe:ased . UPA antigen. D·dime:rs, fi brin monomers, 
f.e:e: pro,ein S amigen and Ihe: ac,ivi,in of IPA . PAI and 
plasminogen in the perfusate ",e:fe: comparable: '0 Ihe 
cor.esponding levels in the: syslemic eirc:ulation (Table 3). 
Discussion 
The rde:vance: of haemos'atie pU2rlle:ters measuled 
during O lT depends on the: 'ype, amOUßl and timin, 
of leplaeeme:n"herapy inua.opera, ivcly. The:rc We:fe: no 
concentratts of clouing faClon or inhibilo,s give:n 10 our 
patie:ntli during Ol T and the: amount of RBC and FFP 
uamfuse:d is clcarly below ,hose repolled ftom othe:, 
et ntrc:s (Table 2). ).6 . '6. '1 Operation time:, cold ischatmic 
time of Ihe graft liver and Ihe: duration of the anhepatic 
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BeUUSt of Ihe bencficial effeci of aplolinin on 
Ihe hacmorrhagic diathesis o~lVcd in Ihe course of 
OL T in former palH::nlS. 11 aprolinin was given prophyl. 
:.!.c!ically as boli "'tin O. ~ " 1<1' KIU Ihret limes during 
OLT. Ncither prolhromboli( side Cffect5 nor impairmcnt 
of renal :tod hepalic (unctions wert obS(rvcd in a study 
ustng very high aplOlinin dosagt (175 x 106 KIUI 
24 h) in p:lIicms wirh polyuauma' 01 in paticms 
undclgoing (lld;ac surgery (5 " [06 KIU I2 h ). L?IO 
There 1ft :1.1 Itut IwO main asp«ts 10 Ix distinguishcd 
in Ihe evaluation of hacmosl:tti{ (hanges du ring O LT. 
(I) In Ihe anhcp:uic pha.sc:' , ff:duccd hcpalic deannce 
of cnzymts and inhibitors. surgical Stress, V1lS<ular 
manipulations :tod thc vcnoycnous bypass may (unh<:! 
detang<: prc-cxisting diSlurbances of haemost:uis. (2) 
Despite extensive flushing of the graft liver in our 
tib'- '" 111 PS 
(glll ('I ( 'I 













pa,ients, con.scrvation fl uid togcther with mediaton 
rdeascd from the gml emer the systemie ejreulation 
during reperfusion. 
Out tcsults demonSU:l.1ed a stcady increasc of tPA 
aCliv ity and amigen levels pcaking immediately before 
Ihe reperfusion phase. Using the same usays we found 
maximal Yalues dcarly Iol'o'Cr than chose repottcd by Potte 
eI tJI.6 We also obscrved a concomi tant increase of uPA 
activity~a result which has not bttn dcsc ribed before. 
Thus, in addition 10 the intrinsie patnway. thc in trinsie 
fibrinoJytie system may be involved in the developmem 
of nypcrfibrinolysis obscrved in TEG. The PAP and 
D-dimer levels took a parallel course 10 thc plasminogen 
act ivators demoll5uating the i" vivo crealion and circet 
of plasmin . 
Immcdiately afler ('('perfusion, an increasc of TAT 
0 .0'" 
, 
Fi,U~ S. Modi»> val" .. offib,inogcn . f~o pro"in S .ntigen (f"O<oin S). a",i,hrombin tu (AT 111) In IOorthotopit li.." I~ lam., · S' ifi 
P ""JUli (~ I;r) .r. $1\0 ..... . for .. r"(1'I< ... 1"<l1tt Tobl. , . "'P 1OfU. 'gn 'COn' 
S,. ",tu.J ~NlIlRio.J 
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• • 
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Ran", «- 104 ~6 - 118 )1- 118 (1-98 
Ran", 33-80 ) 1 - 81 ~-1l }) - 89 
R""I ' 22) - ~H 210- 391 1)7-14( 194 - ~) 
Rang. O. l - H 1.4- '.0 1.2 - 2.7 1.1 - 2.7 
6 
12 - )9 18-42 
18 - U )1-98 
}1-19 42 -76 
IH-H~ 181 - 303 













complcx~s has been repofled~·6 and we have con!irmed 
thot tesulu. In addition, eJevated fibrin monomers and 
decrcasa in AT 111 :lCtiv!ty, free prole!n Santigen and 
fibrinogen levels after reperfusion suggest that a con· 
sumption ofhaeffio.natic raCtors including prothrombin 
activation takes plue. 
The e1evatioru of the acute phase proteiru PAI and 
fibrinogen in the COU[5t' of the reperfusion phase may 
also be explained by gml liver symhesis. 
The graft livet perfusate is a mixlUre of insueaming 
arterial blood and conservation fluid. which explairu the 
fact that most of the haemostatic parameters measllred 
in ,he perfusate are comparable tO or lowet Ihan those 
detetmined in blood sampies of the systemic ci[(ularion 
immc:diall: lr befote repcrfusion (Table ~). In COntrast, 
TAT complexes were elevatea in the perfus;ue, indiating 
an incr~d thrombin formation in the liver graft 
,..he!eas the auivi,ies of ,he protease inhibitors prolein 
C. AT 111 and C.·inhibitor were ovctpfOponionally 
lo,..erea, luggesting their conS\lmption during gr;J{ livet 
perfusion. This could explain the signs of &ssemin· 
ated imravascular coagulalion (DIe) occurr ing after 
reperfusion . 
Furthermore, high uPA activity in contrast 10 low {PA 
activity uw:I antigen concen,ration could Ix mea$llted in 








higher levels in the pcrfusate Ihan in the systemic 
circul.tion . Tbis was followea by an inc(ease of Ihe uPA 
amigen in [he sys{emic ci rculation :tfter repcrfusion. Tbe 
fau thaI uPA llClivity docs not increase llfte! reperfusion 
despile peaking uPA llmigen may be expbined by 
complex inauivat ion of uPA by PAI as weil as by 
tPA.depcndenl and plasmin'ffiediated $CuPA acriYlllion. 
Our resulrs coocerning changes of (he cOllgulaüon and 
fibrinolytic systems in p:uieO{s undergoing OlT confirm 
previous (eporrs' -6 and seem tO advance Ihem , in that 
we have shown that hyperfibrinolysis dneloping mainly 
in the anhepatic phase of OlT preeedes the appe:ltllnce 
of DIC. whieh in IUm may be uiggered by mediators 
from the graft liver er)lering Ihe systemi( cirtulation. 
Tberapculic suggestions derived from these dala may 
inc:lude Ihe supplememation wilh AT III shorrly before 
reperfusion tO antagonilc Ihe increased prolhrombin 
activation ;Jler reperfusion. Funhcrmore. a prolongcd 
OU5hing of the Hvcr in order (0 achieye a reduetion of 
(he entrance of aetive medialOrs from Ihe gml livet in 
{he reeipient's citculation is preferable. 
The relalively small blood USt obscrvcd. compared 
wilh olher group~, '.S.6 may in parr be e~plained by (he 
adminiSHation of aptolinin 10 our palienu as weil as by 
the shon operation (imc . Howcver. OUt rcsuJIS do not 
darify the role of aprotinin in our patienu since a contro! 
fil"'" 6. M~di.., U>d mun lJ>fotinin (on«nl1:uioru in 10 on ..... opi< ~~r u~n.spl.., ... tions. "/>foti"; ........ " .... bcf_.hc InhcpI<i< ptw... 
IU ohe end af.hc .nhrp •• i< pb* U>d 60 min oft., .. porfusion . 
T.ble J . Comp.ri<O<"l of lI.omo.,.,i< p • .,m ••• " ,n ,"" ponll"'o (PI 
of .ho , •• f, li"", ~"h ,h( ." ,.m,. < ... :III.uon ) m,n bofo.e 
• opon,,_ (4 ) 
p>'.,me,ers Rd .. e""r M.d,.n Ron,. P(-4/P) 
,PA oe, 0) - 2.0 , 
'" 
0 - }0.4 0070 
(lU) P 10.4 0 - 1).6 
.PA .e I 2 - 12 ) • 21.4 14 3-~-4 4 0014 
(", I m)) p 11.4 7.2-188 
"PA oe. preltmon>ly • 0. 10 0 - 0 . )2 0 .0)0 
InJ/ml) .on,. <0.1 P 0. 16 0 - 0.)1 
"PA ., ptcltminory , .. , 0 - 3.9) 0.200 
(n,/ml) .. ni. < 0 .7 P .n 0 - 6.00 
C,·mhib"01 n - lJoO • 11.0 )) - 101 "'" ,., p " . 17 - 91 
PA) on 0 - 39 • 84 .0 0-)48 0107 (AU) P 68 .0 0 - 27.) 
pb.sm'nocen 6) - ))0 , ~9 .0 H - N 0. '80 (., P 4l .0 10 - 11 
fibttoocen 1.6 - 40 • 1.91 1. 1 - 2.7 0.0 18 (,li) P ,.,. O.S _ 2.2 
AT 111 71 - 130 , 
" 




26 - )6 
Jlfo .. ;n C 70 - 140 • 24.0 .-,. UMH 
1" P 12.0 0 - 24 
f prot . 5 I, 6) - 1)0 • 82. ) 41 - 98 . "" (., P 70.0 lt - 106 
fibnn mO<'lom •• • 
, .-, O.J86 
(0- ... +) p , .-, 
D·di .... , < 0 .) • 
" 
0-< 0. 199 
(m,/l) P , . 0 - 16 
TAT <omplna 1 0 - ' .1 • '" 
I ) -270 • 00' 
(mc /ml ) P 
'" 
10 - )14 
Tablc ~ . P.,>m< .. rs of ,.n onhotopoc 11 ... , .. ruplan""ofll 
M.di." Ilana< 
Cold ioch •• mir ,im. Imin) )7).) Ho - 744 
nu ... ion of.hc op<'OUOR (h) ,., H 
Ou ... jon of .h( :onb<p>ttc p~ (mm) 8).1 H - 106 
Tin>< of hmpiw .... , (da)"1 
" 
19-1)9 
group wirhout aprot;nin Wti nOI studied . In addition, 
rhe concenu:uion of aptolin;n in rhe plasma did nol 
achicve a level suggcsled tO Ix of lherapculic signifiCa ncc 
by o lher investigatol'J. ' ·• 
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